17.04
-3.17 (-15.69%)
| Penutupan Terdahulu | 20.21 |
| Buka | 17.33 |
| Jumlah Dagangan | 876,311 |
| Purata Dagangan (3B) | 415,896 |
| Modal Pasaran | 483,946,656 |
| Harga / Jualan (P/S) | 1.89 |
| Harga / Buku (P/B) | 0.530 |
| Julat 52 Minggu |
| Margin Keuntungan | -13.94% |
| Margin Operasi (TTM) | -26.95% |
| EPS Cair (TTM) | -1.33 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.74% |
| Nisbah Semasa (MRQ) | 6.32 |
| Aliran Tunai Operasi (OCF TTM) | 9.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.21 M |
| Pulangan Atas Aset (ROA TTM) | -3.69% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Fulgent Genetics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.50 |
|
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 33.42% |
| % Dimiliki oleh Institusi | 54.65% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |